Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128463) titled 'Evaluation on Efficacy and Safety of Switching to Tucatinib Combined with Fulvestrant or Trastuzumab Deruxtecan After Disease Progression in HR-positive/HER2-low Metastatic Breast Cancer' on July 21.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Zhejiang Cancer Hospital
Condition:
breast cancer
Intervention:
Group A :Switching from Trastuzumab Deruxtecan to Capivasertib plus Fulvestrant)
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-08-01
Target Sample Size: Group A :30;Group B:30;
Countries of Recruitment:
China
To know more, visit https://w...